LumaCyte today announced that its analytical approach has been included in the newly published International Organization for Standardization (ISO) global standard for gene delivery systems, ISO 16921 ...
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
In 2023, industry is witnessing a renaissance in viral vector characterization. Spurred by widespread biopharma investment to engineer a new wave of novel capsids and faced with newly launched QbD ...
Analytical methods in differential systems and vector fields combine classical techniques with modern computational approaches to elucidate the intricate dynamics of nonlinear systems. Researchers use ...
As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and ...
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP manufacturing by up to nine months, driven by key ...
CHARLOTTESVILLE, Va., March 31, 2026--(BUSINESS WIRE)--LumaCyte today announced that its analytical approach has been included in the newly published International Organization for Standardization ...
Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma's CMC (chemistry, manufacturing and controls) development Project to accelerate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results